Literature DB >> 24042109

Functional comparison of Plasmodium falciparum transmission-blocking vaccine candidates by the standard membrane-feeding assay.

Kazutoyo Miura1, Eizo Takashima, Bingbing Deng, Gregory Tullo, Ababacar Diouf, Samuel E Moretz, Daria Nikolaeva, Mahamadou Diakite, Rick M Fairhurst, Michael P Fay, Carole A Long, Takafumi Tsuboi.   

Abstract

Recently, there has been a renewed interest in the development of transmission-blocking vaccines (TBV) against Plasmodium falciparum malaria. While several candidate TBVs have been reported, studies directly comparing them in functional assays are limited. To this end, recombinant proteins of TBV candidates Pfs25, Pfs230, and PfHAP2 were expressed in the wheat germ cell-free expression system. Outbred CD-1 mice were immunized twice with the antigens. Two weeks after the second immunization, IgG levels were measured by enzyme-linked immunosorbent assay (ELISA), and IgG functionality was assessed by the standard membrane-feeding assay (SMFA) using cultured P. falciparum NF54 gametocytes and Anopheles stephensi mosquitoes. All three recombinant proteins elicited similar levels of antigen-specific IgG judged by ELISA. When IgGs purified from pools of immune serum were tested at 0.75 mg/ml in the SMFA, all three IgGs showed 97 to 100% inhibition in oocyst intensity compared to control IgG. In two additional independent SMFA evaluations, anti-Pfs25, anti-Pfs230, and anti-PfHAP2 IgGs inhibited oocyst intensity in a dose-dependent manner. When all three data sets were analyzed, anti-Pfs25 antibody showed significantly higher inhibition than the other two antibodies (P < 0.001 for both), while there was no significant difference between the other two (P = 0.15). A proportion of plasma samples collected from adults living in an area of malaria endemicity in Mali recognized Pfs230 and PfHAP2. This is the first study showing that the HAP2 protein of P. falciparum can induce transmission-blocking antibody. The current study supports the possibility of using this system for a comparative study with multiple TBV candidates.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24042109      PMCID: PMC3838000          DOI: 10.1128/IAI.01056-13

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  20 in total

1.  Disruption of Plasmodium falciparum development by antibodies against a conserved mosquito midgut antigen.

Authors:  Rhoel R Dinglasan; Dario E Kalume; Stefan M Kanzok; Anil K Ghosh; Olga Muratova; Akhilesh Pandey; Marcelo Jacobs-Lorena
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-02       Impact factor: 11.205

2.  Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines.

Authors:  Kazutoyo Miura; Andrew C Orcutt; Olga V Muratova; Louis H Miller; Allan Saul; Carole A Long
Journal:  Vaccine       Date:  2007-11-20       Impact factor: 3.641

3.  Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria.

Authors:  Elissa M Malkin; Anna P Durbin; David J Diemert; Jetsumon Sattabongkot; Yimin Wu; Kazutoyo Miura; Carole A Long; Lynn Lambert; Aaron P Miles; Jin Wang; Anthony Stowers; Louis H Miller; Allan Saul
Journal:  Vaccine       Date:  2005-05-02       Impact factor: 3.641

Review 4.  Plasmodium berghei HAP2 induces strong malaria transmission-blocking immunity in vivo and in vitro.

Authors:  Andrew M Blagborough; Robert E Sinden
Journal:  Vaccine       Date:  2009-07-09       Impact factor: 3.641

Review 5.  Proteins of the malaria parasite sexual stages: expression, function and potential for transmission blocking strategies.

Authors:  G Pradel
Journal:  Parasitology       Date:  2007-08-23       Impact factor: 3.234

6.  A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains.

Authors:  D C Kaslow; I A Quakyi; C Syin; M G Raum; D B Keister; J E Coligan; T F McCutchan; L H Miller
Journal:  Nature       Date:  1988-05-05       Impact factor: 49.962

7.  Wheat germ cell-free system-based production of malaria proteins for discovery of novel vaccine candidates.

Authors:  Takafumi Tsuboi; Satoru Takeo; Hideyuki Iriko; Ling Jin; Masateru Tsuchimochi; Shusaku Matsuda; Eun-Taek Han; Hitoshi Otsuki; Osamu Kaneko; Jetsumon Sattabongkot; Rachanee Udomsangpetch; Tatsuya Sawasaki; Motomi Torii; Yaeta Endo
Journal:  Infect Immun       Date:  2008-02-11       Impact factor: 3.441

8.  A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48/45 expressed in Escherichia coli.

Authors:  Debabani Roy Chowdhury; Evelina Angov; Thomas Kariuki; Nirbhay Kumar
Journal:  PLoS One       Date:  2009-07-22       Impact factor: 3.240

9.  Qualification of standard membrane-feeding assay with Plasmodium falciparum malaria and potential improvements for future assays.

Authors:  Kazutoyo Miura; Bingbing Deng; Gregory Tullo; Ababacar Diouf; Samuel E Moretz; Emily Locke; Merribeth Morin; Michael P Fay; Carole A Long
Journal:  PLoS One       Date:  2013-03-06       Impact factor: 3.240

10.  Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.

Authors:  Yimin Wu; Ruth D Ellis; Donna Shaffer; Erica Fontes; Elissa M Malkin; Siddhartha Mahanty; Michael P Fay; David Narum; Kelly Rausch; Aaron P Miles; Joan Aebig; Andrew Orcutt; Olga Muratova; Guanhong Song; Lynn Lambert; Daming Zhu; Kazutoyo Miura; Carole Long; Allan Saul; Louis H Miller; Anna P Durbin
Journal:  PLoS One       Date:  2008-07-09       Impact factor: 3.240

View more
  58 in total

Review 1.  Transmission-Blocking Vaccines: Old Friends and New Prospects.

Authors:  Festus K Acquah; Joshua Adjah; Kim C Williamson; Linda E Amoah
Journal:  Infect Immun       Date:  2019-05-21       Impact factor: 3.441

2.  Immunogenicity studies of proteins forming the T4 phage head surface.

Authors:  Krystyna Dąbrowska; Paulina Miernikiewicz; Agnieszka Piotrowicz; Katarzyna Hodyra; Barbara Owczarek; Dorota Lecion; Zuzanna Kaźmierczak; Andrey Letarov; Andrzej Górski
Journal:  J Virol       Date:  2014-08-20       Impact factor: 5.103

3.  The fibrinogen-like domain of FREP1 protein is a broad-spectrum malaria transmission-blocking vaccine antigen.

Authors:  Guodong Niu; Caio Franc A; Genwei Zhang; Wanlapa Roobsoong; Wang Nguitragool; Xiaohong Wang; Jetsumon Prachumsri; Noah S Butler; Jun Li
Journal:  J Biol Chem       Date:  2017-05-22       Impact factor: 5.157

Review 4.  Determinants of Malaria Transmission at the Population Level.

Authors:  Teun Bousema; Chris Drakeley
Journal:  Cold Spring Harb Perspect Med       Date:  2017-12-01       Impact factor: 6.915

5.  ELISA units, IgG subclass ratio and avidity determined functional activity of mouse anti-Pfs230 antibodies judged by a standard membrane-feeding assay with Plasmodium falciparum.

Authors:  Kazutoyo Miura; Bingbing Deng; Yimin Wu; Luwen Zhou; Thao P Pham; Ababacar Diouf; Chia-Kuei Wu; Shwu-Maan Lee; Jordan L Plieskatt; Merribeth J Morin; Carole A Long
Journal:  Vaccine       Date:  2019-03-05       Impact factor: 3.641

6.  Alga-produced malaria transmission-blocking vaccine candidate Pfs25 formulated with a human use-compatible potent adjuvant induces high-affinity antibodies that block Plasmodium falciparum infection of mosquitoes.

Authors:  Kailash P Patra; Fengwu Li; Darrick Carter; James A Gregory; Sheyenne Baga; Steven G Reed; Stephen P Mayfield; Joseph M Vinetz
Journal:  Infect Immun       Date:  2015-02-17       Impact factor: 3.441

Review 7.  Immune Responses in Malaria.

Authors:  Carole A Long; Fidel Zavala
Journal:  Cold Spring Harb Perspect Med       Date:  2017-08-01       Impact factor: 6.915

8.  Evaluation of Plasmodium vivax HAP2 as a transmission-blocking vaccine candidate.

Authors:  Yue Qiu; Yan Zhao; Fei Liu; Bo Ye; Zhenjun Zhao; Sataporn Thongpoon; Wanlapa Roobsoong; Jetsumon Sattabongkot; Liwang Cui; Qi Fan; Yaming Cao
Journal:  Vaccine       Date:  2020-02-21       Impact factor: 3.641

9.  Evaluation of a Plasmodium-Specific Carrier Protein To Enhance Production of Recombinant Pfs25, a Leading Transmission-Blocking Vaccine Candidate.

Authors:  Elizabeth M Parzych; Kazutoyo Miura; Aarti Ramanathan; Carole A Long; James M Burns
Journal:  Infect Immun       Date:  2017-12-19       Impact factor: 3.441

10.  Transmission-blocking activity is determined by transmission-reducing activity and number of control oocysts in Plasmodium falciparum standard membrane-feeding assay.

Authors:  Kazutoyo Miura; Bruce J Swihart; Bingbing Deng; Luwen Zhou; Thao P Pham; Ababacar Diouf; Timothy Burton; Michael P Fay; Carole A Long
Journal:  Vaccine       Date:  2016-06-29       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.